Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors
Supportive Care in Cancer · 2024-07 · 32 (7)
DOI: 10.1007/s00520-024-08681-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Supportive Care in Cancer, online erschienen am 27.06.2024. Verfasst von Gozde Kavgaci und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. drgozdekavgaci@gmail.com. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Analgesics, Opioid, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hacettepe University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
This study aimed to assess the effects of concurrent opioid analgesic (OA) use with immune checkpoint inhibitors (ICIs) on progression-free survival (PFS) and overall survival (OS).
Methods
In this observational retrospective study, we included advanced cancer patients who received ICIs at Hacettepe University Hospital’s Department of Medical Oncology between June 2018 and January 2023.
Results
Our study included 375 recurrent or metastatic cancer patients treated with ICIs in the first, second line, or beyond. There were no significant differences between the OA-treated and OA-untreated groups regarding median age, age group, gender, primary tumor location, ICI type, or the presence of baseline liver and lung metastases. However, the OA-treated group exhibited a significantly higher proportion of patients who had received three or more prior treatments before initiating ICIs ( p = 0.015). OA-Untreatment was significantly correlated with prolonged mPFS (6.83 vs. 4.30 months, HR 0.59, 95% CI 0.44–0.79, p < 0.001) and mOS (17.05 vs. 7.68 months, HR 0.60, 95% CI 0.45–0.80, p < 0.001).
Conclusions
Our study demonstrates an association between the concurrent use of OAs and reduced OS and PFS in patients treated with ICIs. While OA treatment serves as a surrogate marker for higher disease burden, it may also suggest a potential biological relationship between opioids and immunotherapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. drgozdekavgaci@gmail.com.
- Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
- Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Department of Medical Oncology, Liv Hospital, Ankara, Turkey.
- Department of Medical Oncology, Istinye University Faculty of Medicine, Istanbul, Turkey.
Förderung
- Hacettepe University
Zitieren
APA
Kavgaci, G., Guven, D. C., Kaygusuz, Y., Karaca, E., Dizdar, O., Kilickap, S., Aksoy, S., Erman, M., & Yalcin, S. (2024). Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors. Supportive Care in Cancer, 32(7). https://doi.org/10.1007/s00520-024-08681-2
Vancouver
Kavgaci G, Guven DC, Kaygusuz Y, Karaca E, Dizdar O, Kilickap S, et al. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors. Supportive Care in Cancer. 2024;32(7). doi:10.1007/s00520-024-08681-2
BibTeX
@article{Kavgaci2024,
author = {Kavgaci, Gozde and Guven, Deniz Can and Kaygusuz, Yunus and Karaca, Ece and Dizdar, Omer and Kilickap, Saadettin and Aksoy, Sercan and Erman, Mustafa and Yalcin, Suayib},
title = {Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors},
journal = {Supportive Care in Cancer},
year = {2024},
volume = {32},
number = {7},
doi = {10.1007/s00520-024-08681-2}
}
EUVIMED